VHL and nonpapillary renal cell carcinoma: The underlying correlations between DDC and mutations such as VHL, BAP1, SETD2, and PBRM1 and whether DDC could serve as a new drug target for treating ccRCC patients or boosting immunotherapy response should be investigated in future studies to better guide treatments.